-
EP3644721
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3644721
| EP3644721 - MOUSE MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 20.06.2024 Database last updated on 14.11.2024 | |
| Former | Grant of patent is intended Status updated on 17.10.2023 | ||
| Former | Examination is in progress Status updated on 05.02.2021 | ||
| Former | Request for examination was made Status updated on 03.04.2020 | ||
| Former | The international publication has been made Status updated on 04.01.2019 | ||
| Former | unknown Status updated on 06.08.2018 | Most recent event Tooltip | 20.06.2024 | Application deemed to be withdrawn | published on 24.07.2024 [2024/30] | Applicant(s) | For all designated states Juno Therapeutics, Inc. 400 Dexter Avenue North, Suite 1200 Seattle, WA 98109 / US | [2020/19] | Inventor(s) | 01 /
CHADWICK, Eric Martin 400 Dexter Ave. N Suite 1200 Seattle, WA 98109 / US | 02 /
HAUSE, Ronald James JR. 400 Dexter Ave. N Suite 1200 Seattle, WA 98109 / US | 03 /
JIANG, Yue 400 Dexter Ave. N Suite 1200 Seattle, WA 98109 / US | 04 /
LEVITSKY, Hyam I. 400 Dexter Ave. N Suite 1200 Seattle, WA 98109 / US | 05 /
SALMON, Ruth Amanda 400 Dexter Ave. N Suite 1200 Seattle, WA 98109 / US | 06 /
PONCE, Rafael Angel 400 Dexter Ave. N Suite 1200 Seattle, WA 98109 / US | 07 /
OLSON, Nels Eric 400 Dexter Avenue North Suite 1200 Seattle, WA 98109 / US | [2020/19] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [N/P] |
| Former [2020/19] | Goodfellow, Hugh Robin, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | Application number, filing date | 18745744.5 | 29.06.2018 | [2020/19] | WO2018US40497 | Priority number, date | US201762527030P | 29.06.2017 Original published format: US 201762527030 P | US201762563635P | 26.09.2017 Original published format: US 201762563635 P | US201762584731P | 10.11.2017 Original published format: US 201762584731 P | [2020/19] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019006427 | Date: | 03.01.2019 | Language: | EN | [2019/01] | Type: | A1 Application with search report | No.: | EP3644721 | Date: | 06.05.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.01.2019 takes the place of the publication of the European patent application. | [2020/19] | Search report(s) | International search report - published on: | EP | 03.01.2019 | Classification | IPC: | A01K67/027, C07K16/28, C07K16/30, G01N33/50, A61K35/17 | [2020/19] | CPC: |
C07K16/2803 (EP,US);
A01K67/0271 (EP,US);
A61K31/675 (US);
A61K35/17 (US);
A61K39/4611 (EP);
A61K39/4631 (EP);
A61K39/464412 (EP);
A61K49/0008 (US);
C07K14/7051 (US);
C07K14/70517 (US);
C07K14/70521 (US);
C07K14/70578 (US);
C07K16/30 (EP);
G01N33/5014 (EP,US);
G01N33/5088 (EP,US);
A01K2207/12 (EP,US);
A01K2207/20 (EP,US);
A01K2227/105 (EP,US);
A01K2267/0331 (EP,US);
A61K2039/505 (US);
A61K2039/5156 (US);
A61K2039/5158 (US);
A61K2239/13 (EP);
A61K2239/31 (EP);
A61K2239/38 (EP);
A61K2239/47 (EP);
C07K2317/53 (US);
C07K2317/622 (EP,US);
C07K2319/00 (EP);
C07K2319/02 (US);
C07K2319/03 (US);
C07K2319/30 (US);
C07K2319/33 (US);
C12N2750/14143 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/19] | Extension states | BA | 22.01.2020 | ME | 22.01.2020 | Validation states | KH | 22.01.2020 | MA | 22.01.2020 | MD | 22.01.2020 | TN | 22.01.2020 | Title | German: | MAUSMODELL ZUR AUSWERTUNG VON TOXIZITÄTEN IM ZUSAMMENHANG MIT IMMUNOTHERAPIEN | [2020/19] | English: | MOUSE MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES | [2020/19] | French: | MODÈLE MURIN POUR ÉVALUER DES TOXICITÉS ASSOCIÉES À DES IMMUNOTHÉRAPIES | [2020/19] | Entry into regional phase | 22.01.2020 | National basic fee paid | 22.01.2020 | Designation fee(s) paid | 22.01.2020 | Examination fee paid | Examination procedure | 22.01.2020 | Examination requested [2020/19] | 22.01.2020 | Date on which the examining division has become responsible | 24.08.2020 | Amendment by applicant (claims and/or description) | 09.02.2021 | Despatch of a communication from the examining division (Time limit: M06) | 19.08.2021 | Reply to a communication from the examining division | 23.12.2021 | Despatch of a communication from the examining division (Time limit: M04) | 29.04.2022 | Reply to a communication from the examining division | 24.08.2022 | Despatch of a communication from the examining division (Time limit: M06) | 03.03.2023 | Reply to a communication from the examining division | 18.10.2023 | Communication of intention to grant the patent | 29.02.2024 | Application deemed to be withdrawn, date of legal effect [2024/30] | 21.03.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2024/30] | Fees paid | Renewal fee | 15.06.2020 | Renewal fee patent year 03 | 14.06.2021 | Renewal fee patent year 04 | 13.05.2022 | Renewal fee patent year 05 | 31.03.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO0119967 (UNIV CALIFORNIA [US], et al) [Y] 119-147 * table 13 *; | [XYI] - HEATHER VANSEGGELEN ET AL, "T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, US, (20150630), vol. 23, no. 10, doi:10.1038/mt.2015.119, ISSN 1525-0016, pages 1600 - 1610, XP055310335 [X] 1,2,4-10,18-20,22-25,27,28,31-34,36-38,40-47,49,50,56-58,60,63-65,68,70-72,76-78,80-83,85,86,89-98,101,102,105-108,113 * page 1603 - page 1608 * [Y] 3,15-17,21,26,29,30,48,51-55,59,61,62,69,73-75,79,84,87,88,99,100,103,104,109-112,114-147 [I] 11-14,35,39,66,67 DOI: http://dx.doi.org/10.1038/mt.2015.119 | [Y] - E. J. CHEADLE ET AL, "Differential Role of Th1 and Th2 Cytokines in Autotoxicity Driven by CD19-Specific Second-Generation Chimeric Antigen Receptor T Cells in a Mouse Model", THE JOURNAL OF IMMUNOLOGY, US, (20140312), vol. 192, no. 8, doi:10.4049/jimmunol.1302148, ISSN 0022-1767, pages 3654 - 3665, XP055505466 [Y] 3,15-17,21,26,29,30,48,51-55,59,61,62,69,73-75,79,84,87,88,99,100,103,104,109-112,114-147 * figure 1 * DOI: http://dx.doi.org/10.4049/jimmunol.1302148 | [Y] - E. J. CHEADLE ET AL, "Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells", THE JOURNAL OF IMMUNOLOGY, (20100120), vol. 184, no. 4, doi:10.4049/jimmunol.0901440, ISSN 0022-1767, pages 1885 - 1896, XP055034825 [Y] 3,15-17,21,26,29,30,69,73-75,79,84,87,88 * page 4 - page 5 * DOI: http://dx.doi.org/10.4049/jimmunol.0901440 | [Y] - CHALLICE L BONIFANT ET AL, "Toxicity and management in CAR T-cell therapy", MOLECULAR THERAPY - ONCOLYTICS, (2016), vol. 3, doi:10.1038/mto.2016.11, ISSN 2372-7705, page 16011, XP055500674 [Y] 48,51-55,59,61,62,99,100,103,104,109-112,114-147 * the whole document * DOI: http://dx.doi.org/10.1038/mto.2016.11 | [Y] - FELIPE BEDOYA ET AL, "The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy", MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY, US, (201702), vol. 25, no. 2, doi:10.1016/j.ymthe.2016.11.011, ISSN 1525-0016, pages 314 - 320, XP055505280 [Y] 48,51-55,59,61,62,99,100,103,104,109-112,114-118 * the whole document * DOI: http://dx.doi.org/10.1016/j.ymthe.2016.11.011 | [Y] - TURTLE CAMERON J ET AL, "Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose", vol. 128, no. 22, ISSN 0006-4971, (20161202), page 1852, BLOOD; 58TH ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH), AMERICAN SOCIETY OF HEMATOLOGY, US; SAN DIEGO, CA, USA, URL: http://www.bloodjournal.org/content/128/22/1852, XP009503772 [Y] 48,51-55,59,61,62,99,100,103,104,109-112,114-147 * the whole document * | [Y] - Roberts Margo, "Scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products", (20161202), URL: http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2016/12/WC500217499.pdf, (20180906), XP055505278 [Y] 48,51-55,59,61,62,99,100,103,104,109-112,114-118 * page 11 * | [Y] - D. T. TEACHEY ET AL, "Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia", CANCER DISCOVERY, US, (20160413), vol. 6, no. 6, doi:10.1158/2159-8290.CD-16-0040, ISSN 2159-8274, pages 664 - 679, XP055314474 [Y] 48,51-55,59,61,62,99,100,103,104,109-112,114-118 * figure 1 * DOI: http://dx.doi.org/10.1158/2159-8290.CD-16-0040 | [A] - SHIRLEY M BARTIDO, "The regulation of CAR-T cells", CELL AND GENE THERAPY INSIGHTS, (20170504), vol. 3, no. 4, doi:10.18609/cgti.2017.026, ISSN 2059-7800, pages 239 - 253, XP055505287 [A] 1-147 * page 246 - page 247 * DOI: http://dx.doi.org/10.18609/cgti.2017.026 | by applicant | US8252592 | US8450329 | US50401 | US4452773 | US4795698 | EP0090505 | US5200084 | US5219740 | EP0452342 | US5424297 | US5504090 | WO9613593 | WO9618105 | US5527814 | US5538848 | US5545627 | US5565566 | US5635517 | US5670501 | US5712291 | WO9803502 | US5786360 | US5798368 | WO9854170 | US5861405 | WO9918129 | WO9920758 | US5925517 | WO9940196 | WO9952552 | US5981524 | WO9960120 | WO0014257 | US6040177 | US6066642 | US6111090 | US6117998 | US6174670 | WO0103720 | US6207453 | US6232297 | US6281230 | US6313131 | US6316471 | US6322771 | US6326390 | US6326145 | US6329144 | US6335349 | US2002045643 | US6380239 | US6395754 | US6403613 | US6410319 | WO02055083 | WO02059106 | WO02068414 | US6451995 | US2002131960 | US6458810 | US6476052 | US2003045552 | WO03020763 | US6635427 | US2004047858 | WO2004033685 | WO2005007190 | WO2005055808 | WO2005115451 | WO2006000830 | WO2006009755 | US7025962 | US7070995 | WO2006083289 | US7091353 | US7132255 | WO2006121168 | US7141575 | WO2007005874 | US7235240 | US7244759 | US7265209 | WO2007133822 | EP1866339 | US7320991 | US7354762 | WO2008063888 | US7405219 | US7446190 | US7446179 | US7446191 | WO2008147482 | WO2008154252 | US2009082299 | US7510687 | US7514444 | WO2009072003 | WO2009099553 | WO2009101611 | WO2009114335 | US7618632 | WO2010003118 | US7645755 | US2010028330 | WO2010019570 | WO2010027827 | WO2010033140 | WO2010077634 | US2010247521 | US7812135 | WO2010125571 | US2011003380 | EP2277543 | US7893075 | US2011044998 | WO2011028683 | US2011081311 | WO2011044186 | WO2011051726 | US7943743 | WO2011066342 | WO2011090754 | US8008309 | US8008449 | US8080554 | US2012039906 | US8124084 | US2012114649 | US2012141413 | US2012177598 | WO2012129514 | US8324353 | US8339645 | EP2537416 | WO2013006490 | US8354509 | WO2013026837 | US8389282 | US8388967 | US8398282 | WO2013039954 | WO2013054331 | WO2013071154 | WO2013082366 | US2013149337 | US2013156774 | US8479118 | US8476284 | EP1947183 | US8497277 | WO2013123061 | WO2013126726 | US2013287748 | WO2013166321 | US8586023 | US8591886 | US8609089 | WO2014001802 | WO2014022332 | WO2014031687 | US2014056922 | US2014065141 | WO2014055668 | US8697711 | WO2014059251 | US8703780 | US8716315 | US8716301 | US8735403 | US8754090 | US8754091 | US8802374 | US8822647 | US2014271635 | US2014271618 | US8883500 | US2014377240 | US8957079 | US8987279 | US8999999 | US2015119267 | WO2015079417 | US2015210769 | US2015218274 | US9125889 | US2015259420 | US9181257 | US2016032248 | US9296753 | US2016313300 | - CHIA et al., Nature Genetics, (20050000), vol. 37, no. 11, pages 1181 - 1186 | - FESTING, ILAR Journal, (20140000), vol. 55, no. 3, pages 399 - 404 | - ULLAND et al., Nature Communications, (20160000), vol. 7, page 13180 | - BENDANDI et al., J Vaccines Immunol | - NAGORSEN; BAUERLE, Exp Cell Res, (20110000), vol. 317, pages 1255 - 1260 | - HOLLIGER et al., Prot Eng, (19960000), vol. 9, pages 299 - 305 | - KIPRIYANOV et al., J Mol Biol, (19990000), vol. 293, pages 41 - 66 | - SEIMETZ et al., Cancer Treat Rev, (20100000), vol. 36, pages 458 - 467 | - SADELAIN et al., Cancer Discov., (20130400), vol. 3, no. 4, pages 388 - 398 | - DAVILA et al., PLoS ONE, (20130000), vol. 8, no. 4, page e61338 | - TURTLE et al., Curr. Opin. Immunol., (20121000), vol. 24, no. 5, pages 633 - 39 | - WU et al., Cancer, (20120318), vol. 2, pages 160 - 75 | - KOCHENDERFER et al., Nature Reviews Clinical Oncology, (20130000), vol. 10, pages 267 - 276 | - WANG et al., J. Immunother., (20120000), vol. 35, no. 9, pages 689 - 701 | - BRENTJENS et al., Sci Transl Med., (20130000), vol. 5, no. 177 | - HUDECEK et al., Clin. Cancer Res., (20130000), vol. 19, page 3153 | - FEDOROV et al., Sci. Transl. Medicine, (20131200), vol. 5, no. 215 | - DE FELIPE, Genetic Vaccines and Ther., (20040000), vol. 2, page 13 | - DEFELIPE et al., Traffic, (20040000), vol. 5, pages 616 - 626 | - JORES et al., Proc. Nat'l Acad. Sci. U.S.A., (19900000), vol. 87, page 9138 | - CHOTHIA et al., "7", EMBO J., (19880000), page 3745 | - LEFRANC et al., Dev. Comp. Immunol., (20030000), vol. 27, page 55 | - KOTB, Clinical Microbiology Reviews, (19950000), vol. 8, pages 411 - 426 | - HOLLER et al., Nat Immunol, (20030000), vol. 4, pages 55 - 62 | - HOLLER et al., Proc Natl Acad Sci USA, (20000000), vol. 97, pages 5387 - 92 | - LI et al., Nat Biotechnol, (20050000), vol. 23, pages 349 - 54 | - CHERVIN et al., J Immunol Methods, (20080000), vol. 339, pages 175 - 84 | - SINGH; RAGHAVA, Bioinformatics, (20010000), vol. 17, no. 12, pages 1236 - 1237 | - SCHULER et al., Immunoinformatics Methods in Molecular Biology, (20070000), vol. 409, no. 1, pages 75 - 93 | - SOO HOO, W. F. et al., PNAS (USA, (19920000), vol. 89, page 4759 | - WULFING, C.; PLUCKTHUN, A., J. Mol. Biol., (19940000), vol. 242, page 655 | - KURUCZ, I. et al., PNAS (USA, (19930000), vol. 90, page 3830 | - SCHLUETER, C. J. et al., J. Mol. Biol., (19960000), vol. 256, page 859 | - CARLENS et al., Exp Hematol, (20000000), vol. 28, no. 10, pages 1137 - 46 | - ALONSO-CAMINO et al., Mol Ther Nucl Acids, (20130000), vol. 2, page e93 | - PARK et al., Trends Biotechnol., (20111129), vol. 11, pages 550 - 557 | - MILLER; ROSMAN, BioTechniques, (19890000), vol. 7, pages 980 - 990 | - MILLER, A. D., Human Gene Therapy, (19900000), vol. 1, pages 5 - 14 | - SCARPA et al., Virology, (19910000), vol. 180, pages 849 - 852 | - BURNS et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 8033 - 8037 | - BORIS-LAWRIE; TEMIN, Cur. Opin. Genet. Develop., (19930000), vol. 3, pages 102 - 109 | - COOPER et al., Blood, (20030000), vol. 101, pages 1637 - 1644 | - VERHOEYEN et al., Methods Mol Biol., (20090000), vol. 506, pages 97 - 114 | - CAVALIERI et al., Blood, (20030000), vol. 102, no. 2, pages 497 - 505 | - CHICAYBAM et al., PLoS ONE, (20130000), vol. 8, no. 3, page e60298 | - VAN TEDELOO et al., Gene Therapy, (20000000), vol. 7, no. 16, pages 1431 - 1437 | - MANURI et al., Hum Gene Ther, (20100000), vol. 21, no. 4, pages 427 - 437 | - SHARMA et al., Molec TherNucl Acids, (20130000), vol. 2, page e74 | - HUANG et al., Methods Mol Biol, (20090000), vol. 506, pages 115 - 126 | - Current Protocols in Molecular Biology, John Wiley & Sons | - JOHNSTON, Nature, (19900000), vol. 346, pages 776 - 777 | - BRASH et al., Mol. Cell Biol., (19870000), vol. 7, pages 2031 - 2034 | - CHEADLE et al., "Chimeric antigen receptors for T-cell based therapy", Methods Mol Biol., (20120000), vol. 907, doi:doi:10.1007/978-1-61779-974-7_36, pages 645 - 66, XP009179541 DOI: http://dx.doi.org/10.1007/978-1-61779-974-7_36 | - BARRETT et al., Chimeric Antigen Receptor Therapy for Cancer Annual Review of Medicine, (20140000), vol. 65, pages 333 - 347 | - LUPTON S. D. et al., Mol. and Cell Biol., (19910000), vol. 11, no. 6 | - RIDDELL et al., Human Gene Therapy, (19920000), vol. 3, pages 319 - 338 | - TERAKURA et al., Blood, (20120000), vol. 1, pages 72 - 82 | - WANG et al., JImmunother., (20120000), vol. 35, no. 9, pages 689 - 701 | - Methods in Molecular Medicine, vol. 58 | - Metastasis Research Protocols, vol. 2 | - Cell Behavior In Vitro and In Vivo, Humana Press Inc., pages 17 - 25 | - KLEBANOFF et al., JImmunother., (20120000), vol. 35, no. 9, pages 651 - 660 | - WANG et al., J Immunother., (20120000), vol. 35, no. 9, pages 689 - 701 | - CHO et al., Lab Chip, (20100000), vol. 10, pages 1567 - 1573 | - GODIN et al., J Biophoton., (20080000), vol. 1, no. 5, pages 355 - 376 | - KLEBANOFF et al., J Immunother., (20120000), vol. 35, no. 9, pages 651 - 660 | - Journal of Immunology, vol. 122, no. 2, pages 549 - 554 | - GRANER et al., "Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma", Clin Cancer Res, (20000000), vol. 6, no. 3, pages 909 - 915, XP002639946 | - "The Gene Ontology Consortium", Nucleic Acids Research, (20080000), vol. 36, pages 440 - 4 | - SMITH et al., Nature Biotechnology, (20070000), vol. 25, no. 11, pages 1251 - 5 | - "Methods in Molecular Biology", DESSIMOZ, C; SKUNCA, N., The Gene Ontology Handbook, Springer, page 1446 | - CARBON et al., Bioinformatics., (20090000), vol. 25, no. 2, pages 288 - 9 | - GOTZ et al., Nucleic Acids Research, (20080000), vol. 36, no. 10, pages 3420 - 35 | - GUST et al., Cancer Discov, (20170000), vol. 7, no. 12, pages 1 - 16 | - DANTZER et al., Nat Rev Neurosci, (20080000), vol. 9, page 46 | - VARATHARAJ; GALEA, Brain, Behavior, and Immunity, (20170000), vol. 60, pages 1 - 12 | - HARMURN, C. H. et al., Nature, (19900000), vol. 343, pages 336 - 340 | - GONG et al., J Exp Med., (19970707), vol. 186, no. 1, pages 131 - 137 | - SHAHRARA et al., J Immunol, (20080000), vol. 180, pages 3447 - 3456 | - DOBBER et al., Cell Immunol., (19950200), vol. 160, no. 2, pages 185 - 92 | - OZMEN et al., J Immunol., (19930401), vol. 150, no. 7, pages 2698 - 705 | - HUNTER et al., J Immunol., (20050601), vol. 174, no. 11, pages 7368 - 75 | - FLEISCHMANN et al., Annals of the rheumatic diseases, (20060000), vol. 65, no. 8, pages 1006 - 12 | - MULLER et al., Bioorganic & Medicinal Chemistry Letters, (19990000), vol. 9, no. 11, page 1625 | - MESA et al., Nature Reviews Drug Discovery, (20120000), vol. 11, no. 2, pages 103 - 104 | - CONWAY et al., Proc Natl Acad Sci USA, (20050000), vol. 102, no. 44, pages 16078 - 83 | - DAGHER et al., Journal of Neuroinflammation, (20150000), vol. 12, no. 139 | - OHNO et al., Mol Cancer Ther., (20060000), vol. 5, no. 11, pages 2634 - 43 | - VON TRESCKOW et al., Clin Cancer Res., (20150000), vol. 21, no. 8 | - MANTHEY et al., Mol Cancer Ther., (20090000), vol. 8, no. 11, pages 3151 - 61 | - PYONTECK et al., Nat Med., (20130000), vol. 19, no. 10, pages 1264 - 1272 | - RIES et al., Cancer Cell, (20140000), vol. 25, no. 6, pages 846 - 59 | - SBARBA, J Clin Cell Immunol., (20150000), vol. 6, no. 6 | - YRJANHEIKKI et al., PNAS, (19980000), vol. 95, no. 26, pages 15769 - 15774 | - YOUNGER et al., Pain Med., (20090000), vol. 10, no. 4, pages 663 - 672 | - VALERA et al., J. Neuroinflammation, (20150000), vol. 12, no. 93 | - RAMIREZ et al., J. Neurosci, (20050000), vol. 25, no. 8, pages 1904 - 13 | - HOING et al., Cell Stem Cell., (20121102), vol. 11, no. 5, pages 620 - 32 | - BASU et al., Indian J Crit Care Med., (20140000), vol. 18, no. 12, pages 822 - 824 | - PARDOLL, Nature Reviews Cancer, (20120000), vol. 12, pages 252 - 264 | - SHINOHARA et al., Genomics, (19950000), vol. 23, pages 704 - 6 | - BLANK et al., Cancer Immunol Immunother, (20070000), vol. 56, pages 739 - 45 | - FINGER et al., Gene, (19970000), vol. 197, pages 177 - 87 | - TOPALIAN et al., N Engl J Med, (20120000), vol. 366, pages 2443 - 54 | - LIPSON et al., Clin Cancer Res, (20130000), vol. 19, pages 462 - 8 | - BERGER et al., Clin Cancer Res, (20080000), vol. 14, pages 3044 - 51 | - GILDENER-LEAPMAN et al., Oral Oncol, (20130000), vol. 49, pages 1089 - 96 | - MENZIES; LONG, Ther Adv Med Oncol, (20130000), vol. 5, pages 278 - 85 | - BRAHMER et al., N Eng J Med, (20120000), vol. 366, pages 2455 - 65 | - OTT et al., Clin Cancer Res, (20130000), vol. 19, pages 5300 - 9 | - RADVANYI et al., Clin Cancer Res, (20130000), vol. 19, page 5541 | - BERGER et al., Clin Cancer Res, (20080000), vol. 14, pages 13044 - 51 | - ROBERT; GHIRINGHELLI, Oncologist, (20090000), vol. 14, pages 848 - 61 | - OTT et al., Clin Cancer Res, (20130000), vol. 19, page 5300 | - WEBER, Oncologist, (20070000), vol. 12, pages 864 - 72 | - WADA et al., J Transl Med, (20130000), vol. 11, page 89 | - NGIOW et al., Cancer Res, (20110000), vol. 71, pages 3540 - 3551 | - MONNEY et al., Nature, (20020000), vol. 415, pages 536 - 541 | - ZHENG et al., PLoS One, (20110000), vol. 6, no. 6, page e21146 | - OSHIMA, K. et al., Nihon Rinsho., (20140000), vol. 72, no. 6, pages 1130 - 5 | - MILLRINE, D. et al., TrendsMolMed., (20170000), vol. 23, no. 4, pages 348 - 364 | - COLLINS et al., Biochem J., (20170000), vol. 474, no. 7, pages 1127 - 1147 | - BERTILACCIO et al., Blood, (20130000), vol. 122, page 4171 | - OTAHAL et al., Oncoimmunology, (20160000), vol. 5, no. 4, page e1115940 | - FECTEAU et al., Blood, (20140000), vol. 124, no. 10, pages 1637 - 1644 | - KURAMITSU et al., Cancer Gene Therapy, (20150000), vol. 22, pages 487 - 495 | - OTAHAL et al., Oncoimmunology, (20160000), vol. 5, no. 4, page el 115940 | - LIM et al., Haematologica, (20100000), vol. 95, no. 1, pages 135 - 43 | - CRONSTEIN et al., Ann. N.Y. Acad. Sci., (19850000), vol. 451, page 291 | - ROBERTS et al., Biochem. J., (19850000), vol. 227, page 669 | - SCHRIER et al., J. Immunol., (19860000), vol. 137, page 3284 | - CRONSTEIN et al., Clinical Immunol. Immunopath., (19870000), vol. 42, page 76 | - SITKOVSKY et al., Cancer Immunol Res, (20140000), vol. 2, no. 7, pages 598 - 605 | - OHTA et al., ProcNatl Acad Sci U S A, (20060000), vol. 103, pages 13132 - 13137 | - JIN et al., Cancer Res., (20100000), vol. 70, no. 6, pages 2245 - 2255 | - LEONE et al., Computational and Structural Biotechnology Journal, (20150000), vol. 13, pages 265 - 272 | - BEAVIS et al., Proc Natl Acad Sci U S A, (20130000), vol. 110, pages 14711 - 14716 | - PINNA, A., Expert Opin Investig Drugs, (20090000), vol. 18, pages 1619 - 1631 | - HERSHFIELD, Hum Mutat., (19950000), vol. 5, page 107 | - CARROLL; ASHCROFT, Expert. Rev. Mol. Med., (20050000), vol. 7, no. 6, pages 1 - 16 | - ALLARD et al., Clin Cancer Res, (20130000), vol. 19, no. 20, pages 5626 - 5635 | - HAUSLER et al., Am J Transl Res, (20140000), vol. 6, no. 2, pages 129 - 139 | - ZHANG, B., Cancer Res., (20100000), vol. 70, no. 16, pages 6407 - 6411 | - SHENDURE et al., Nat. Rev. Genet., (20040000), vol. 5, pages 335 - 44 | - NOWROUSIAN, EUK., Cell, (20100000), vol. 9, no. 9, pages 1300 - 1310 | - KIMBLER et al., PLoS ONE, (20010000), vol. 7, no. 7, page e41229 | - WANG et al., Annals of Clinical and Laboratory science, (20120000), vol. 1, no. 42, pages 14 - 20 | - CARRILLO et al., SIAM J Applied Math, (19880000), vol. 48, page 1073 | WO1991US08442 | WO1994US05601 | WO1997US13375 |